https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accounts-payable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accounts-receivable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accrued-liabilities-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accrued-salaries-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/accumulated-depreciation https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/additional-paid-in-capital https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/additional-paid-in-capital-common-stock https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/adjustment-for-amortization https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/amortization https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/amortization-of-debt-discount-premium https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/bank-overdrafts https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/basic-shares https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/capital-expenditures https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cash https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cash-and-equivalents https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cash-equivalents-at-carrying-value https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cash-fdic-insured-amount https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cash-flow-breakdown https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/common-dividends-paid https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/common-stock-value https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/concept-stock-issued-tag-2 https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/convertible-notes-payable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/convertible-notes-payable-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cost-of-goods-sold https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/current-assets https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/current-federal-tax-expense-benefit https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/current-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/debt-decrease-forgiveness https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/debt-unamortized-discount https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/deferred-tax-assets-gross https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/depreciation https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/depreciation-and-amortization https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/derivative-liabilities-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/development-stage-enterprise-deficit-accumulated-during-development-stage https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/dividends-common-stock https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/due-from-related-parties https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/due-from-related-parties-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/due-to-related-parties-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/due-to-related-parties-current-and-noncurrent https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/effective-tax-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/eps-basic https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/equity-issuance-per-share-amount https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/fair-value-assumptions-risk-free-interest-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/fair-value-assumptions-weighted-average-volatility-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/fair-value-net-derivative-asset-liability-change-in-unrealized-gain-loss https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/fair-value-net-derivative-asset-liability-unobservable-inputs-reconciliation-issues https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/financing-cash-flow https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/finite-lived-intangible-assets-gross https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/gains-losses-on-extinguishment-of-debt https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/general-and-administrative-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/gross-profit https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/income-tax https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/income-taxes-paid https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-accounts-payable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-accounts-payable-trade https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-accounts-receivable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-accrued-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-accrued-salaries https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-due-to-related-parties https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-employee-related-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-other-current-assets https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-other-current-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/increase-decrease-in-prepaid-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/interest-paid https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/investing-cash-flow https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/litigation-settlement-amount-awarded-to-other-party https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/net-cash-from-financing-activities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/net-cash-from-investing-activities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/net-cash-from-operating-activities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/net-change-in-cash https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/net-income https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/noninterest-expense-transfer-agent-and-custodian-fees https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-cash-flow https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-costs-and-expenses https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-expenses https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-income https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-leases-future-minimum-payments-receivable-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-leases-future-minimum-payments-receivable-in-three-years https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-leases-future-minimum-payments-receivable-in-two-years https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/operating-loss-carryforwards https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-current-assets https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-current-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-general-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-income https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-income-2 https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-noncurrent-assets https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/other-noninterest-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/paid-in-capital-other https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/payment-of-financing-and-stock-issuance-costs https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/payments-of-distributions-to-affiliates https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/payments-of-financing-costs https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/payments-to-acquire-loans-receivable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-shares-facts https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/preferred-stock-value https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/prepaid-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/prepaid-expense-current https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/prepaid-expense-current-and-noncurrent https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-loans https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-notes-payable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-other-debt https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-related-party-debt https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-repayments-of-bank-overdrafts https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-sale-of-loans-receivable https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/proceeds-from-stock-issued https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/professional-fees https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/property-plant-equipment https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/provision-for-doubtful-accounts https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/public-float https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/related-party-transaction-due-from-to-related-party https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/retained-earnings https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/revenue https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/sales-revenue-net https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/sga-expense https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/share-price https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shareholders-equity https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shares-authorized https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shares-issued https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shares-issued-price-per-share https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shares-issued-value-issued-for-services https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/shares-outstanding-2 https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-shares-issued-shares-issued-for-cash https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-shares-issued-shares-new-issues https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-shares-issued-shares-other https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-shares-issued-value-issued-for-cash https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-shares-issued-value-other https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stock-issued-value-of-shares-issued-for-acquisitions https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/stockholders-equity-including-portion-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/tax-rate-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/tax-rate-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/tax-reconciliation-change-in-deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/technology-services-costs https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/total-assets https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/total-liabilities https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/proto-script-pharmaceutical-corp/weighted-average-number-of-share-outstanding-basic-and-diluted